PakAlumni Worldwide: The Global Social Network
Pakistan Pharma Among World's Top 3 Fastest Growing
Pakistan pharmaceutical industry and market are among the world's top 3 fastest growing, according to IQVIA health market research firm based in the United States. Pakistan’s domestic pharmaceutical firms sales have grown 13.1% compounded annually in the last 4 years, outperforming multinational companies (MNCs), which saw global growth of 9.34% CAGR. Pakistan's pharma sector is growing faster than in other emerging markets like Bangladesh, Brazil, India, Russia and Vietnam.
Emerging faster than the MNCs, the quarterly revenues of the local Pakistani pharmaceutical companies surged to Rs. 320 billion in the quarter ending March 31, 2020, compared with Rs. 195.75 billion as of March 31, 2016. Similarly, MNCs increased their quarterly sales in Pakistan to Rs. 143.2 billion at the end of the first quarter of 2020, up from Rs. 100.2 billion in Q12016, according to Pakistani media reports. Pakistan exported $217.04 million worth of pharma products during 2019, according to the United Nations COMTRADE database on international trade.
|
Pakistan Pharma Growth Among Top Fastest in the World. Source: IQVIA |
Medicine spending growth in the emerging pharmaceutical ("pharmerging") markets continues to slow compared to the past five years and is projected to grow at 5–8% through 2023, according to US-based global market research firm IQVIA.
|
Although China, Brazil and India have the largest medicine spending within the pharmerging markets, Turkey, Egypt and Pakistan are forecast to have the greatest growth between 2019 and 2023. Pharmerging market growth continues to derive primarily from increasing per capita use, but some markets are seeing wider uptake of newer medicines as patients’ ability to afford their share of costs improves with economic growth.
Pakistan's top 5 pharma companies, including GSK, Abbott, and AGP Pharma, saw their profits jump 37% in Q1/2020 over the same period last year, to Rs2.6 billion. In the same quarter, profits of 13 consumer giants, including Nestle, Packages, Pakistan Tobacco and Colgate, remained flat amid COVID19 pandemic.
In growing recognition of Pakistan's pharmaceutical sector, the US-based Gilead Sciences recently chose to license COVID19 drug Remdesivir to Pakistan's Ferozsons pharmaceutical company. Other Remdisivir licensees include pharma companies in India. Gilead said it signed non-exclusive licensing pacts with 5 generic drugmakers based in India and Pakistan, allowing them make and sell Remdesivir for 127 countries.
Related Links:
Vast Majority of Pakistanis Support Imran Khan's Handling of Covid19 Crisis
Pakistani-American Woman Featured in Netflix Documentary "Pandemic"
Coronavirus Lockdown, Lives and Livelihoods
Can Pakistan Effectively Respond to Coronavirus Outbreak?
Pakistan's Computer Services Exports
Pakistan Mobile Phone Manufacturing
How Grim is Pakistan's Social Sector Progress?
Major Tipping Point: Pakistan Middle Class Grows to 55% Of Population
Pakistan Fares Marginally Better Than India On Disease Burdens
Can Imran Khan Lead Pakistan to the Next Level?
Clean Energy Revolution in Pakistan
Democracy vs Dictatorship in Pakistan
Pakistan Child Health Indicators
Pakistan's Balance of Payments Crisis
Conspiracy Theories About Pakistan Elections"
Riaz Haq
Prime minister honours 30 top exporters of Pakistan. Getz Pharma receives the highest export award in the pharmaceutical industry
Getz Pharma among 30 companies recognised as top pharmaceutical exporters in 2025
https://profit.pakistantoday.com.pk/2026/02/09/prime-minister-honou...
Founded in 1995, Getz Pharma became Pakistan’s leading pharmaceutical company within just 15 years of inception. It has been steadily building its exports by raising standards to meet the most demanding international benchmarks. Its success in global markets is rooted in an unwavering commitment to quality and compliance, reflected in accreditations from leading regulatory agencies of regulated markets, including the World Health Organization-Geneva, Eurasian Economic Union (EAEU) and PIC/S. Every pack exported to more than 45 countries is manufactured at Getz Pharma’s internationally accredited and approved facilities at Karachi. This export leadership is the result of sustained vision and bold investment decisions. Over the past 15 years, Getz Pharma has invested nearly PKR 50 billion in cutting‑edge manufacturing plants, quality management systems, and advanced technologies. Getz Pharma is the first company in Pakistan that set up a Biotechnology Manufacturing Facility in 2007, where it manufactured the first Human Insulin (Insuget) and Insulin Analogues (Basagin) in Pakistan. The company remained the only manufacturer of insulins in Pakistan for over 17 years.
Feb 9
Riaz Haq
Russian firm to invest $80 million in Pakistan to produce insulin with local partner
https://www.arabnews.com/node/2638278/pakistan
Project includes plants to produce insulin locally from its active ingredient by 2031
DRAP approves prices for Russian insulin, links them to local production commitment
KARACHI: Russian firm Zavod Medsintez LLC and its local importer Genetics Pharmaceuticals Private Limited plan to invest about $80 million in Pakistan’s pharmaceutical sector over the next six years to start producing insulin locally, according to a notification the Drug Regulatory Authority of Pakistan (DRAP) shared with Arab News on Tuesday.
The two companies will build an aseptic filling plant and an insulin manufacturing facility in the South Asian nation in two stages which, DRAP said, should be respectively completed by Dec. 2028 and Dec. 2031.
The plan surfaced as DRAP allowed the Russian manufacturer and its local partners to sell Rosinsulin R, Rosinsulin C and Rosinsulin M 30/70 insulin at maximum retail prices ranging from Rs1,399.33 ($5.01) per 10 milliliter vial to Rs3,235 ($11.6) per pack of five cartridges.
“The Drug Regulatory Authority of Pakistan with the approval of the federal government is pleased to fix maximum retail prices,” read the notification dated March 17.
The move would bring fresh investment to Pakistan where Prime Minister Shehbaz Sharif’s government is trying hard to woo foreign direct investment (FDI) in the country of more than 240 million people. FDI, however, has been moving south in recent years and has declined more than 33 percent to $1.19 billion this fiscal year during July-Feb. period, show State Bank of Pakistan data.
The DRAP made the notified prices conditional and said the price revision is granted on the explicit understanding that Zavod Medsintez and Genetics Pharmaceuticals would “immediately” start the establishment of the relevant manufacturing facility plant and commencement of local production of Active Pharmaceutical Ingredient (API) in two stages.
API is the essential, biologically active component within a drug responsible for producing the intended health effects, such as curing, treating, or preventing diseases.
“The first stage is the construction of an aseptic filling plant” at approximately $20 million, it said. The construction of the unit for bulk import and dedicated biological unit for aseptic filling of insulin and its derivatives should be completed by Dec. 31, 2028, the regulator said.
“The second stage is the construction of an API production plant (at) approximately $60 million,” it added.
The project will also include development and transfer of technology for the production of biotechnological products (insulins) from the API, i.e., from purification of API to packaging of its finished form, C Biotech, and should be completed by Dec. 31, 2031, the authority said, adding it would monitor progress and require the company to share stage-wise detailed timelines for investment.
“In case of non-compliance with the commitment of setting up manufacturing facility and manufacturing in Pakistan, the product registration shall be canceled,” the DRAP warned.
May 13
Riaz Haq
https://www.chinadailyhk.com/hk/article/636655#Pakistan-China-pharm...
Speaking at the conference, Prime Minister's Special Assistant on Industries and Production Haroon Akhtar Khan said the event would play a key role in promoting industrial cooperation, attracting foreign direct investment, and facilitating technology transfer.
He said the conference brought together leading Chinese companies represented by a large number of delegates, along with more than 200 Pakistani companies, making it one of the largest business gatherings between the two countries in the pharmaceutical, healthcare, and biotechnology sectors.
Khan said the conference aims to accelerate industrial development, increase foreign investment, promote local manufacturing, generate employment opportunities, and modernize Pakistan's healthcare industry.
He added that discussions focused on six priority areas, including active pharmaceutical ingredients, biotechnology and vaccines, medical devices, generic medicines and injectables, clinical trials and research, as well as herbal medicines and Traditional Chinese Medicine.
Highlighting Pakistan's dependence on imported pharmaceutical inputs, Khan said the country currently imports around 90 percent of the raw materials required by its pharmaceutical industry.
He said Chinese investment, advanced technology, and expertise could significantly strengthen domestic manufacturing, reduce reliance on imports, improve supply chain resilience, and boost exports.
Addressing the gathering, Chinese Ambassador to Pakistan Jiang Zaidong reaffirmed China's commitment to strengthening economic and industrial cooperation with Pakistan. He said the Chinese embassy would continue to facilitate closer engagement between enterprises of the two countries and provide support to expand bilateral investment and business cooperation.
Jiang also expressed hope that Pakistan would continue to provide a stable security environment and favorable business conditions for Chinese enterprises operating in the country.
Noting that China's vast market presents new opportunities for Pakistan, Jiang said enhanced business cooperation would deliver mutual benefits while strengthening the all-weather strategic cooperative partnership between the two countries.
The conference, which runs from Friday to Saturday, features B2B matchmaking sessions and one-on-one meetings between companies from both countries to form joint ventures, technology partnerships, and long-term industrial collaboration.
on Saturday